Oncology And US Dominate Daiichi's New Mid-Term Plan
Vision Beyond Core ADCs
Executive Summary
Major Japanese firm sets targets under a new mid-term plan that envisages the US oncology sector leading growth and revenues, and also casts an eye to novel assets beyond three pillar antibody-drug conjugates and new digital technologies.